Eris Lifesciences Acquires Remaining 30% of Swiss Parenterals
Filing Summary
Eris Lifesciences Ltd has announced the acquisition of the remaining 30% shareholding in Swiss Parenterals Limited, making it a wholly owned subsidiary. The transaction involves a share swap valued at INR 423 Crores, with Eris issuing 23,06,372 equity shares to Mr. Naishadh Shah, Director of Swiss Parenterals. This acquisition is classified as a related party transaction and is expected to be completed by March 31, 2026. The move aims to consolidate Eris’s position in the pharmaceuticals sector, enhancing operational synergy and financial consolidation.
Eris Lifesciences Ltd has approved the acquisition of the remaining 30% share capital of Swiss Parenterals Limited, a subsidiary of Eris. This acquisition will result in Swiss Parenterals becoming a wholly owned subsidiary of Eris. The decision was made during the Board of Directors meeting held on November 24, 2025. The transaction is structured as a share swap, with Eris issuing equity shares to Mr. Naishadh Shah, a Director at Swiss Parenterals.
The financial terms of the acquisition involve a total purchase consideration of INR 423 Crores. This consideration will be discharged through the issuance of 23,06,372 equity shares of Eris Lifesciences to Mr. Naishadh Shah. The shares are issued at a price of INR 1,835.35 per share, as determined by an independent valuation report. This transaction is classified as a related party transaction under SEBI regulations, given Mr. Shah’s role as a Director at Swiss Parenterals.
Operationally, the acquisition aims to consolidate Eris’s position in the pharmaceuticals industry. Swiss Parenterals, which specializes in parenteral products, has a presence in over 80 countries. The acquisition is expected to provide Eris with full managerial control and enable complete financial consolidation. This move is intended to improve cost efficiencies and streamline governance within the company.
The timeline for the completion of this acquisition is set tentatively before March 31, 2026. The process involves issuing a notice of postal ballot to Eris shareholders to obtain their consent for the equity share issuance to Mr. Naishadh Shah. The cut-off date for determining eligible members for voting is November 21, 2025.
The parties involved in this transaction include Eris Lifesciences Ltd, Swiss Parenterals Limited, and Mr. Naishadh Shah. Eris currently holds a 70% stake in Swiss Parenterals and will acquire the remaining 30% from Mr. Shah. The transaction is conducted at arm’s length, with no interest from Eris’s promoter group in the transaction.
Swiss Parenterals Limited, incorporated on February 4, 1997, has shown consistent growth in its turnover over the past three years, with figures of INR 220 Crores, INR 283 Crores, and INR 351 Crores for FY 2022-23, FY 2023-24, and FY 2024-25, respectively. The acquisition aligns with Eris’s strategy to enhance its operational synergy and strengthen its strategic presence in the pharmaceuticals sector.
Eris Lifesciences Ltd is focused on expanding its footprint in the pharmaceuticals industry through strategic acquisitions and operational enhancements. The company aims to consolidate its market position and improve its financial and operational efficiencies through such strategic moves.